Solvonis Therapeutics plc (FRA:J4I)

Market Cap	9.92M -55.0%
Revenue (ttm)	n/a
Net Income	-6.58M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0005 - 0.0035
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorde...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: J4I

Financial Performance

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error